secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001420720-24-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio Q1 fiscal 2025: net loss $4.0M ($0.46/sh), no revenue; advancing myostatin NHP study
--------------------------------------------------------------------------------

- No revenue for quarter ended Sep 30, 2024; net loss from continuing ops $4.0M ($0.46/sh) vs $5.1M ($4.24/sh) YoY.
- R&D and G&A expenses decreased ~20% YoY to $4.1M as part of cash preservation strategy.
- Cash, equivalents, and restricted cash $11.3M at Sep 30, 2024 (incl $0.2M restricted).
- Collaboration with AstralBio: lead molecule for muscle wasting/obesity dosed in NHP study; early readouts expected early 2025.
- Appointed Kristi Sarno as SVP of Business Development effective Aug 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/0001420720-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/ibio-20240930x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer